Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 10/20 | 0.60 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSH | P09668 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29675079 | 1.00 | CXCR4 (0.60) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| Omiganan SCHEMBL27824120 | 0.99 | CXCR4 (0.60) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| Omiganan SCHEMBL29410943 | 0.98 | CXCR4 (0.59) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL29675119 | 0.97 | CXCR4 (0.59) | CXCR4KISS1ROPRM1OPRK1 | |
| SCHEMBL29674929 | 0.97 | CXCR4 (0.59) | CXCR4KISS1ROPRM1OPRK1 | |
| SCHEMBL29412263 | 0.96 | CXCR4 (0.61) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL30273393 | 0.93 | CXCR4 (0.61) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL29443798 | 0.91 | CXCR4 (0.60) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL29367784 | 0.91 | NTSR2 (0.62) | CXCR4NTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL30498028 | 0.89 | OPRM1 (0.65) | OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116953219-A | Fluorescent array sensor for multiple bacteria identification and detection method thereof | 南通大学 | 2023-10-27 | — | — | CN | claimed |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4495237-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2026-05-13 | — | — | EP | disclosed |
| WO-2026042045-A1 | INDOLICIDINE-CONTAINING COMPOSITIONS FOR PERSONAL CARE/HYGIENE APPLICATIONS | ITC LIMITED (IN) | 2026-02-26 | — | — | WO | disclosed |
| EP-4694931-A1 | EXTRAHEPATIC DELIVERY OF DOUBLE-STRANDED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250382324-A1 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4658280-A2 | SIX MEMBERED RING CONTAINING OLIGOMERS | Alnylam Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250304613-A1 | AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE CONJUGATION APPROACH | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250304957-A1 | SINGLE-STRANDED LOOP OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2025-10-02 | — | — | US | disclosed |
| EP-3456317-B1 | DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS | ALNYLAM PHARMACEUTICALS INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20220177885-A1 | ENDOSOMAL CLEAVABLE LINKERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| CN-107661240-B | Submicron emulsion repair stock solution composition, preparation method thereof and cosmetic composition containing submicron emulsion repair stock solution composition | 山东千色生物科技有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20220143189-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-05-12 | — | — | US | disclosed |
| US-20220127604-A1 | REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220125823-A1 | EXTRAHEPATIC DELIVERY | BANK OF AMERICA, N.A. | 2022-04-28 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220106593-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-11286482-B2 | Endosomal cleavable linkers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3969052-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | Alnylam Pharmaceuticals Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-107661240-A | A kind of Submicron Emulsion repairs stoste composition, its preparation method and includes its cosmetic composition | 济南佐康商贸有限公司 | 2018-02-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106593-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | SNRPE, DDX21, RNMT | CXCR4 1402/4885NTSR2 1356/4885NTSR1 1118/4885 |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | RNASEL, NSUN2, ADAR | CXCR4 2789/4885NTSR2 1910/4885NTSR1 1861/4885 |
| US-20220125823-A1 | EXTRAHEPATIC DELIVERY | RNASE1, LDLR, HAVCR2 | CXCR4 1101/4885NTSR2 384/4885NTSR1 388/4885 |
| US-20220143189-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | HAVCR2, B3GAT3, CSGALNACT1 | CXCR4 641/4885NTSR2 344/4885NTSR1 172/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | CXCR4 1732/4885NTSR2 1673/4885NTSR1 1334/4885 |
| US-20250382324-A1 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | POLM, PCNA, POLRMT | CXCR4 2500/4885NTSR2 3712/4885NTSR1 3170/4885 |
| US-20250304613-A1 | AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE CONJUGATION APPROACH | AOC2, RTCB, AOC3 | CXCR4 2444/4885NTSR2 3834/4885NTSR1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.